Search Result

Results for "

Haloperidol

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Adrenergic Receptor (1) COX (2) Dopamine Receptor (12) Drug Metabolite (2) GABA Receptor (1) iGluR (1) Imidazoline Receptor (1) Isotope-Labeled Compounds (5) mGluR (1) Monoamine Oxidase (1) nAChR (1) NO Synthase (2) Opioid Receptor (1) Reference Standards (2)
By Research Areas:	Cancer (6) Inflammation/Immunology (2) Neurological Disease (17)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-14538

*Haloperidol* Maximum Cited Publications 15 Publications Verification	Dopamine Receptor	Neurological Disease Cancer
Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

HY-107969

Haloperidol decanoate	Dopamine Receptor COX NO Synthase	Neurological Disease Cancer
Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-14538R

Haloperidol (Standard)	Reference Standards Dopamine Receptor	Neurological Disease Cancer
Haloperidol (Standard) is the analytical standard of Haloperidol. This product is intended for research and analytical applications. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

HY-14538S

Haloperidol-d4	Dopamine Receptor	Neurological Disease
Haloperidol-d₄ is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.

HY-137546

Reduced Haloperidol Haloperidol metabolite II	Drug Metabolite
Reduced Haloperidol (Haloperidol metabolite II) is an antipsychotic compound with neurotransmitter modulating activity. Reduced Haloperidol is commonly used to inhibit schizophrenia and other psychotic disorders. Reduced Haloperidol helps reduce the occurrence of hallucinations and delusions by inhibiting the activity of dopamine receptors.

HY-107969R

Haloperidol decanoate (Standard)	Dopamine Receptor Reference Standards COX NO Synthase	Neurological Disease
Haloperidol decanoate (Standard) is the analytical standard of Haloperidol decanoate. This product is intended for research and analytical applications. Haloperidol decanoate is a depot preparation of haloperidol, a commonly used butyrophenone derivative with antipsychotic activity. Haloperidol decanoate can increase the striatal D₂ receptor in rat. Haloperidol decanoate can improve conditions of psychoses (mainly schizophrenia). Haloperidol decanoate can lead to increased accumulation of the dopamine metabolites homo-vanillic acid. Haloperidol decanoate can reduce intestinal transport, increase gastric emptying and reduce acid output in rat model .

HY-14538B

Haloperidol lactate	Dopamine Receptor	Neurological Disease Cancer
Haloperidol lactate is a potent antipsychotic agent. Haloperidol lactate can be used in acute and chronic schizophrenia and gilles de la tourette's syndrome. Haloperidol lactate has the potential for the research of psychotic disorders .

HY-137546S

*Reduced Haloperidol-d4* Haloperidol metabolite II-d₄	Isotope-Labeled Compounds	Others
Reduced Haloperidol-d₄ is the deuterium labeled Reduced Haloperidol .

HY-14538S3

Haloperidol-13C6	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Haloperidol- ¹³C₆ is the ¹³C₆ labeled Haloperidol. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

HY-14538S2

Haloperidol-d4 N-Oxide	Isotope-Labeled Compounds Dopamine Receptor	Neurological Disease
Haloperidol-d₄ N-Oxide is the deuterium labeled Haloperidol. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic .

HY-14538A

Haloperidol hydrochloride	Dopamine Receptor	Neurological Disease Cancer
Haloperidol hydrochloride is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

HY-14538S1

Haloperidol-d4-1	Dopamine Receptor	Neurological Disease
Haloperidol-d₄-1 is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.

HY-112015

Deschlorohaloperidol R-1838	Dopamine Receptor	Neurological Disease
Deschlorohaloperidol (compound 8h) is an analogue of Haloperidol (HY-14538). Haloperidol is a dopamine D2 receptor (D2R) antagonist for schizophrenia .

HY-102086

MSX3	Adenosine Receptor	Neurological Disease
MSX3 is a potent antagonist of adenosine A2A that can reverse the effects of the dopamine antagonist Haloperidol (HY-14538) on effort-related decision making in a T-maze cost/benefit procedure .

HY-14866

Raseglurant ADX-10059	mGluR	Neurological Disease
Raseglurant (ADX-10059) is a mGlu5 receptor negative allosteric modulator. Raseglurant is effective against migraine. Raseglurant reduces the Haloperidol (HY-14538)-induced catalepsy in mice .

HY-115722

(S)-(-)-MRJF22	Drug Metabolite	Cancer
(S)-(-)-MRJF22 is haloperidol metabolite II valproate ester. (S)-(-)-MRJF22 exhibits the high antimigratory effects in endothelial and tumor cells. (S)-(-)-MRJF22 is a potential multifunctional agent against uveal melanoma .

HY-115860

TAS-4	iGluR	Neurological Disease
TAS-4 is a potent and selective mGluR4 positive allosteric modulator with significant anti-Parkinson's disease activity. TAS-4 is able to show efficacy when used alone or in combination with l-DOPA. TAS-4 is able to reverse haloperidol-induced spasticity when administered alone. TAS-4 enhances the contralateral rotation behavior induced by l-DOPA in a dose-dependent manner. TAS-4 combined with low-dose l-DOPA shows anti-Parkinson's effects similar to full-dose l-DOPA without exacerbating abnormal motor side effects .

HY-171472

A-86929	Dopamine Receptor	Neurological Disease
A-86929 is a highly potent and selective dopamine D₁ receptor agonist with a pK_i value of 7.3. In the 6-OHDA (HY-B1081)-induced unilateral nigrostriatal lesion rat model, A-86929 significantly induces rotational behavior. It also improves motor function in the MPTP (HY-15608)-induced Parkinson's disease marmoset model. Additionally, A-86929 demonstrates potential therapeutic value in reducing cocaine-seeking behavior in rats and reversing Haloperidol (HY-14538)-induced cognitive deficits in rhesus monkeys. A-86929 can be used for research in neurological disorders .

HY-W700834

Harman-d3	Isotope-Labeled Compounds	Neurological Disease Inflammation/Immunology
Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits *haloperidol* and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-W777360

Harman-13C2,15N	Isotope-Labeled Compounds Adrenergic Receptor Monoamine Oxidase nAChR Opioid Receptor Imidazoline Receptor GABA Receptor	Neurological Disease Inflammation/Immunology
Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits *haloperidol* and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Product Name	Chemical Structure

HY-14538S

Haloperidol-d4
Haloperidol-d₄ is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.

HY-14538S1

Haloperidol-d4-1
Haloperidol-d₄-1 is deuterium labeled haloperidol, and the latter is a potent dopamine D2 receptor antagonist.

HY-137546S

*Reduced Haloperidol-d4*
Reduced Haloperidol-d₄ is the deuterium labeled Reduced Haloperidol .

HY-14538S3

Haloperidol-13C6
Haloperidol- ¹³C₆ is the ¹³C₆ labeled Haloperidol. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic.

HY-14538S2

Haloperidol-d4 N-Oxide
Haloperidol-d₄ N-Oxide is the deuterium labeled Haloperidol. Haloperidol is a potent dopamine D2 receptor antagonist, widely used as an antipsychotic .

HY-W700834

Harman-d3
Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits *haloperidol* and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Harman-d3

Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-W777360

Harman-13C2,15N
Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits *haloperidol* and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Harman-13C2,15N

Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Product Name		Classification

HY-102086

MSX3		Alkynes
MSX3 is a potent antagonist of adenosine A2A that can reverse the effects of the dopamine antagonist Haloperidol (HY-14538) on effort-related decision making in a T-maze cost/benefit procedure .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.